MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc., a global leader in medical dermatology, today announced that the U.S. FDA accepted its supplemental New Drug Application (sNDA) for ANZUPGO® (delgocitinib) cream for the treatment of pediatric patients aged 12 to 17 years with moderate to severe chronic hand eczema (CHE). ANZUPGO cream is a topical and non-steroidal pan-Janus kinase (JAK) inhibitor currently approved in the U.S. for the treatment of moderate to severe chronic hand eczema (CHE) in
2026 Copyright © News-Matic.com. All Rights Reserved
